Clinical trial · Interventional
Pazopanib for Metastatic Alveolar Soft Part Sarcoma
A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma
NCT02113826CI-TRIAL-00030166terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual rate
Summary
Brief summary (as posted)
Alveolar soft part sarcoma (ASPS), a rare subset of STS (\<1%) harbors t(X;17)(p11;q25) translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high expression of angiogenic factors, sunitinib and cediranib produced overall response rates of 55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Alveolar Soft Part Sarcoma | Alveolar Soft Part Sarcoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pazopanib | Drug | Pazopanib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pazopanib
- description
- Pazopanib 800mg po qd until disease progression
- interventionNames
- Drug: Pazopanib
Primary outcomes (1)
- measure
- Overall response rate (ORR)
- timeFrame
- One year
- description
- ORR based on RECIST v1.1
Secondary outcomes (3)
- measure
- Number of Participants with Adverse Events
- timeFrame
- One year
- description
- Safety based on CTCAE v4.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: * Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion at stage IV or at relapse * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Measurable lesion defined by RECIST v1.1 * Chemo-naïve or prior chemotherapies * Adequate organ function Exclusion Criteria: * Prior malignancies * Active CNS disease * High-risk for gastrointestinal bleeding * Significant cardiovascular disease * Uncontrolled hypertension * Bleeding diathesis
References
Publications (1)
- DERIVEDKim M, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, Kim DW, Heo DS. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. Oncologist. 2019 Jan;24(1):20-e29. doi: 10.1634/theoncologist.2018-0464. Epub 2018 Sep 25. PMID 30254189